Semma Therapeutics raises $114m for novel diabetes treatment - The Boston Globe
Sernova: Perfekter Partner für Diabetes-Programm von Evotec? - shareribs.com - Technology - IT und Kommunikation
Vertex Targets Type 1 Diabetes Cure with Acquisition of Semma Therapeutics – ISPE Boston
Diabetes: Medtronic joins $44m round for Semma Therapeutics - MassDevice
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy | Nature Reviews Endocrinology
A single patient is producing insulin after treatment with Vertex's new diabetes cell therapy | Fierce Biotech
Semma Therapeutics Acquired by Vertex Pharmaceuticals for $950M : 2019 Reports : Report Library : Publications : Juvenile Diabetes Cure Alliance (JDCA)
Semma Therapeutics, Backed by the JDRF T1D Fund, Acquired by Major Biopharma Company - JDRF
Creating the next cell therapies for diabetes – Eric Bender
Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes | Business Wire
Vertex Bets $950 Million on Stem Cells to Cure Diabetes | Fortune
Semma Therapeutics raises $114 million in Series B financing for Type 1 diabetes novel cell therapy - ConvergenceRI
Semma Therapeutics Announces Pre-Clinical Proof-of-Concept in Two Lead Programs in Type 1 Diabetes | Business Wire
Vertex to buy Semma Therapeutics for $950m in cash
Diabetes: Encapsulating the problem | Nature
Semma gets $44 million in funding for cell therapy for T1D
Harvard diabetes researcher details science behind potential breakthrough – Harvard Gazette
Semma Therapeutics developing stem cell therapy for Type 1 diabetes | Drug Store News
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff | The Motley Fool
Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells - ScienceDirect
Vertex plunks down $950M for stem cell player Semma Therapeutics | Fierce Biotech
Semma Therapeutics Raises $114 Million for Stem Cell Diabetes Treatment
